AlphaTON Capital Corp. is a biotechnology company, which engages in the research and development of immuno-oncology therapies for patients with cancer. The firm is focused on building and managing a strategic reserve of The Open Network (TON) tokens and developing the Telegram ecosystem. The firm implements a treasury strategy that combines direct token acquisition, validator operations, and strategic ecosystem investments to generate sustainable returns for shareholders. Through its operations, the Company provides public market investors with institutional-grade exposure to the TON ecosystem and Telegram's billion user platform. The company is also advancing therapies that target known checkpoint resistance pathways to achieve durable treatment response and improve quality of life for patients. The firm engages in the drug development process and provides strategic counsel to guide development of immunotherapy assets and asset combinations.
最新の財務諸表(Form-10K)によると、AlphaTON Capital Corpの総資産は$2で、純損失は$-6です。
ATONの主要な財務比率は何ですか?
AlphaTON Capital Corpの流動比率は1、純利益率は0、1株当たり売上高は$0です。
AlphaTON Capital Corpの収益はセグメントまたは地域別にどのように分けられていますか?
AlphaTON Capital Corp の最大収益セグメントは For Commercial Use で、最新の利益発表における収益は 186,747,000,000 です。地域別に見ると、Japan が AlphaTON Capital Corp の主要市場であり、収益は 391,785,000,000 です。